COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN

被引：0
|
作者：
Yamaguchi, M. [1 ]
Maeda, T. [1 ]
Morimoto, K. [1 ]
Chen, W. [1 ]
Moriwaki, K. [1 ]
Shimozuma, K. [1 ]
机构：
[1] Ritsumeikan Univ, Kyoto 26, Japan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE260
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
    Lang, Yitian
    Chai, Qingqing
    Tao, Wenqi
    Liao, Yahui
    Liu, Xiaoyan
    Wu, Bin
    [J]. BREAST, 2023, 68 : 173 - 180
  • [2] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey
    Delphine Loirat
    Kevin Punie
    Aditya Bardia
    Véronique Diéras
    Florence Dalenc
    Jennifer R. Diamond
    Christel Fontaine
    Grace Wang
    Hope S. Rugo
    Sara A. Hurvitz
    Kevin Kalinsky
    Joyce O’Shaughnessy
    Sibylle Loibl
    Luca Gianni
    Martine Piccart
    Yanni Zhu
    Rosemary Delaney
    See Phan
    Javier Cortés
    [J]. npj Breast Cancer, 8
  • [3] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [4] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
    Carey, Lisa A.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Dieras, Veronique
    Dalenc, Florence
    Diamond, Jennifer R.
    Fontaine, Christel
    Wang, Grace
    Rugo, Hope S.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Loibl, Sibylle
    Gianni, Luca
    Piccart, Martine
    Zhu, Yanni
    Delaney, Rosemary
    Phan, See
    Cortes, Javier
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [5] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Xie, Jiao
    Li, SiNi
    Li, YaMin
    Li, JianHe
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [6] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie
    SiNi Li
    YaMin Li
    JianHe Li
    [J]. BMC Health Services Research, 23
  • [7] Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
    Kathpalia, Meghavi
    Sharma, Anurag
    Kaur, Navkiran
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (01) : 44 - 53
  • [8] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [9] Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Bhave, Manali Ajay
    Ntalla, Ioanna
    Lai, Catherine
    Sjekloca, Nikoleta
    Stwalley, Brian
    Stokes, Michael
    Taylor, Aliki
    Nanda, Rita
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024,
  • [10] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
12345